Ono Venture Investment, Inc. (OVI) is the corporate venture capital arm of Ono Pharmaceutical Co.,Ltd. ,
an R&D-oriented pharmaceutical company succeeded in delivery of “First in class”
medicines to patients such as OPDIVO® (nivolumab).

Priority Areas

  • Oncology

  • Immunology

  • Neurology

  • Specialty

To fulfill our mission as a Corporate Venture Capital, OVI prioritizes to make investment in novel startups possessing products and
platforms potentially with high synergy to R&D of our parent company, Ono Pharmaceutical Co.,Ltd. .